Mitsubishi Tanabe Pharma America will present 11 studies at the American Academy of Neurology 2025 Annual Meeting, including research on investigational ND0612 for Parkinson's disease and RADICAVA formulations for ALS.
A Phase III trial led by University College London reveals AstraZeneca's diabetes drug Bydureon (exenatide) failed to slow Parkinson's disease progression over 96 weeks.
Mitsubishi Tanabe Pharma America (MTPA) presented data on ND0612, an investigational continuous subcutaneous infusion of levodopa/carbidopa, at the Parkinson Study Group (PSG) meeting.
The Parkinson's disease (PD) therapeutic market faces unmet needs, notably the absence of neuroprotective/disease-modifying therapies (DMTs) and treatments for non-motor symptoms.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.